Patients who are current or past smokers are at additional increased risk. In a large, randomized, postmarketing study comparing another JAK inhibitor with TNF blockers in RA patients ≥50 years old with at least one CV risk factor, a higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) was observed with the JAK inhibitor. Advise patients to limit sunlight exposure by wearing protective clothing and using sunscreen. Periodic skin examination is recommended for patients who are at increased risk for skin cancer. NMSCs have been reported in patients treated with RINVOQ. With RINVOQ, consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients with a known malignancy (other than a successfully treated NMSC), patients who develop a malignancy when on treatment, and patients who are current or past smokers. In a large, randomized, postmarketing safety study comparing another JAK inhibitor with TNF blockers in RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer ), lymphomas, and lung cancer (in current or past smokers) was observed with the JAK inhibitor. Lymphoma and other malignancies have been observed in patients treated with RINVOQ. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with RINVOQ. In a large, randomized, postmarketing safety study comparing another Janus kinase (JAK) inhibitor with tumor necrosis factor (TNF) blockers in rheumatoid arthritis (RA) patients ≥50 years old with at least one cardiovascular (CV) risk factor, a higher rate of all-cause mortality, including sudden CV death, was observed with the JAK inhibitor. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with RINVOQ, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.
0 Comments
Leave a Reply. |